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A 50-year-old male with a hypertensive crisis with 
deep hypokalaemia, metabolic alkalosis, and symp-
toms of muscle weakness and numbness was admitted 
to the hospital two years after the initial diagnosis of 
hypertension. Serum aldosterone level was elevated, 
and plasma renin activity was lowered (Fig. 1A). Al-
dosterone-to-renin ratio exceeded 100 ng/dL/ng/mL/h 
[cut-off value > 20–40 (1)]. Computed tomography 
(CT) of the abdomen revealed a tumour in the right 
adrenal gland, size 32 × 26 × 31 mm (Fig. 1B). The ra-
diological description was as follows: “the unenhanced 
attenuation of 29 HU (Hounsfield Units), 74 HU one 
minute after contrast infusion and 48 HU in the late 
phase, resulting in the absolute percentage wash-out 
value of 57%”. Consequently, lipid poor adenoma was 
recognised. The diagnosis of primary hyperaldosteron-
ism was confirmed in saline infusion test, and adrenal 
venous sampling showed lateralisation of aldosterone 
secretion to the right adrenal gland. The patient un-
derwent laparoscopic adrenalectomy. Histopathology 
revealed a 4 cm fragmented tumour with unexpected 
features of atypical mitosis, mitotic rate 6/50 high-power 
fields, sinusoids invasion, and < 5% of clear cells. Ki67 
index proliferation was high (7–8%), and the tumour 
met criteria of adrenocortical carcinoma. After adrenal-
ectomy, both hypertension and hypokalaemia resolved. 
The patient was referred to our Department, where 
mitotane treatment was introduced. Due to significant 
liver enzyme elevation the therapy was withdrawn after 
only five months. To date, 67 months after surgery, the 
patient is free of recurrence as well as biochemical and 
clinical features of hyperaldosteronism.  
Hypertension is regarded as one of the most frequent 
cardiac disorders. About 10–20% of hypertensives 
have secondary hypertension. Primary aldosteronism 
(PA) is the commonest form, with approximately 10% 
of unselected hypertensives affected [1]. PA is almost 
always caused by benign lesions. In exceptional cases, 
adrenocortical carcinoma (ACC), an orphan malig-
nancy with heterogenous clinical phenotype, can be 
a source of autonomous aldosterone production [2]. 
The typical presentation of ACC is Cushing’s syndrome 
and/or hyperandrogenism. Although the co-secretion 
of several adrenal hormones including aldosterone is 
also a hallmark of ACC, pure aldosteronism is atypical 
and extremely rare (approx. 2.5% of all functional ACC 
cases [3]).
Careful evaluation of every adrenal tumour, even 
with univocal primary aldosteronism phenotype, can 
help to avoid pitfalls in non-routine situations. Abnormal 
cortisol after 1 mg dexamethasone suppression as well as 
elevated androgens levels could have been indicative for 
adrenal malignancy in the reported case; however, they 
were not performed. What is more, all patients with PA 
should undergo abdominal CT and/or magnetic reso-
nance. As the described case shows, the cessation of the 
diagnostic process with only spironolactone therapy in 
patients with clinical suspicion of PA can have dramatic 
consequences and should not be practiced. According to 
Endocrine Society guidelines [1], excluding masses that 
may represent malignancy is the first diagnostic goal in 
every patient with hyperaldosteronism. Typically, large 
masses are at greater risk of malignancy; however, small 
ACCs and aldosterone-producing ACCs (APACs) have 
also been reported [2, 4]. Tumours with density ≤ 10 HU 
in non-contrast CT generally do not need further 
radiological evaluation. All other lesions should be 
treated with caution. Although unenhanced attenua-
tion values subtly exceeding 10 HU are typical for lipid 
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To conclude, precaution in the approach to every 
adrenal mass is of great importance in order not to miss 
atypical ACC cases. 
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poor adenomas, one should consider values close to 30 
HU suspicious, regardless of hormonal status. Absolute 
percentage wash-out (APW) values characteristic for 
lipid poor adenomas are more than 50% and 60% 10 
and 15 minutes after contrast administration, respec-
tively. Surprisingly, in the case discussed above, the 
re-evaluation of CT images showed slightly different 
attenuation values than previously noted:  34 HU, 48 
HU, and 45 HU before, 1 minute, and 15 minutes after 
contrast infusion (Fig. 1C–E). In consequence, APW was 
only 21%. However, even the previously calculated APW 
of 57% was incorrect for the 15th minute of wash-out and 
corresponded to suspicious imaging phenotype. 
In the case described, the time gap from first CT to 
adrenalectomy was as long as a year because of the mis-
leading radiological description suggesting lipid-poor 
adenoma. Fortunately, the course of the disease was 
favourable with no distant metastases. Adrenocortical 
carcinoma is considered an aggressive tumour of rapid 
clinical course and poor prognosis with unexpected, 
even late recurrences [5]. However, less dynamic cours-
es of the disease have also been reported for APACs 
[2]. However, close monitoring of each ACC patient 
after surgery is necessary. One should also note that 
the change of hormonal profile of a recurrent tumour 
may rarely occur due to dedifferentiation of cells with 
altered steroidogenic enzymes profile. 
Figure 1. A. Hormonal test results. B. Computed tomography (CT) of the abdomen showing the tumour in the right adrenal gland. C.–E. 
Re-evaluation of CT images showing suspicious attenuation values before, 1, and 15 minutes after contrast administration, respectively
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